

Report to:	Public Board of Directors	Agenda item:	10
Date of Meeting:	Wednesday 5 May 2021		

Title of Report:	Finance and Performance Committee Update Report
Status:	For Discussion
Sponsor:	Jeremy Boss, Chair of the Finance and Performance Committee
Author:	Jeremy Boss, Chair of the Finance and Performance Committee
Appendices	None

Purpose

This report summarises the discussions, recommendations and approvals made by the Finance and Performance Committee on 14 April 2021, to provide the Board with an update of the Committee's activities.

Background

The Finance and Performance Committee holds delegated responsibility from the Board of Directors; this report provides evidence to satisfy the Board that the tasks required to meet those responsibilities are being carried out.

Business Undertaken

The Committee agreed to increase the frequency of the meetings from 6 a year to 10.

The committee agreed that the proposed BAF included all that was expected but felt that there was also a need for a "system BAF".

It was identified that the two key areas affecting performance were COVID and PHASE 3. It was reported that elective activity was still an issue, notably with regard to Ultrasound.

The Committee reviewed the Improving Patient Flow Together slides, it was noted that there had been positive movement in a number of metrics but the one metric that had not improved was the medically fit to discharge patients.

The Committee reviewed the outline business case for the single EPR project for BSW and for this to move to the Full Business Case stage. They also acknowledged the staff input required and recognised that there would need to be clear understanding of the implications on each individual Trust at the Full Business Case stage.

An update was provided on the capital plan and the proposals for capital next year.

The Deputy Director of Finance provided an update on the Budget 21/22 and discussed the risks to the Trust on delivering the plan. The areas of focus were identified as elective recovery plans, COVID spend reduction, and the transformation programme.

Key Risks and their impact on the Organisation
The provider of choice for the BSW ONE EPR has not been selected at this stage. Whether or not Cerner is the chosen solution will create a very different risk profile for the RUH individually.
Key Decisions
<ul style="list-style-type: none"> • Recommendation that the Board approves the continuation of BSW One EPR Outline Business Case to Full Business Case.
Exceptions and Challenges
Nothing impacted on the Committee's ability to undertake its business.
Governance and Other Business
Finance and Performance Committee meets bi-monthly and the Committee's Terms of Reference are reviewed annually. The Committee's membership consists of the Non-Executives, the Chair, and the Chairs of the Non-Clinical Governance Committee, and the Clinical Governance Committee.
Future Business
In addition to standing items, the Committee will consider: <ul style="list-style-type: none"> • Financial strategy update • Initial evaluation of the committee effectiveness
Recommendations
The Board is asked to note this report.